Calliditas Therapeutics AB
11 clinical trials · Sponsor
◉ Watch Calliditas Therapeutics AB
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy (NCT06712407) | Calliditas Therapeutics AB | 2024-12-17 |
| A Study to Evaluate Setanaxib in Patients With Alport Syndrome (NCT06274489) | Calliditas Therapeutics AB | 2023-11-27 |
| Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) (NCT04541043) | Calliditas Therapeutics AB | 2020-11-17 |
| Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects (NCT04327089) | Calliditas Therapeutics AB | 2020-06-24 |
| Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets (NCT03740217) | Calliditas Therapeutics AB | 2018-12-19 |
| Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (NCT03643965) | Calliditas Therapeutics AB | 2018-09-05 |
Track Calliditas Therapeutics AB automatically
Every clearance here is in the API, with alerts when new ones post.